RxDoctor Payments Data

Dhaval Mehta, MD

Internal Medicine · Monroeville, PANPI 1902060312

Payments from drug & device makers

$79,256in general payments, 2019–2025

Across 130 payments — averaging $609.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$20K
  • AstraZeneca$18K
  • Pharmacyclics LLC, An Abbvie Company$16K
  • Sanofi$6K
  • Verastem, Inc.$6K
  • Karyopharm Therapeutics Inc.$2K
  • plus $11K from 15 others

What the payments were for

  • Consulting fees$34,25179%
  • Speaking & faculty fees$8,08819%
  • Travel & lodging$250%
  • Food & beverage$8662%
  • Education$3161%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$79,256 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$85,168
Medicare patients
341
Services billed
962

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide95$1,305,987
RevlimidLenalidomide78$1,293,978
IbrancePalbociclib74$1,167,703
ImbruvicaIbrutinib37$692,391
VerzenioAbemaciclib36$543,114
PomalystPomalidomide16$360,743
JakafiRuxolitinib Phosphate13$246,935
XtandiEnzalutamide14$200,140
NubeqaDarolutamide16$193,535
CalquenceAcalabrutinib Maleate12$185,363
VenclextaVenetoclax17$181,637
KisqaliRibociclib Succinate11$167,572
EliquisApixaban77$59,907
Abiraterone Acetate25$58,498
XareltoRivaroxaban33$44,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$2,001$1,293,97878 claims
PfizerIbrance, Eliquis$20,035$1,227,610151 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$15,771$692,39137 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$11$360,74316 claims
Astellas Pharma US IncXtandi$100$200,14014 claims
AstraZenecaCalquence$18,032$185,36312 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$1,515$58,49825 claims
Johnson & JohnsonXarelto$1,768$44,39433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Monroeville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →